AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation
Shots:
- AbbVie and OSE Immunotherapeutics have entered into a strategic collaboration for the development of OSE-230 (currently under pre-clinical development) for the treatment of chronic & severe inflammation
- The collaboration grants AbbVie an exclusive license to develop, manufacture & commercialize OSE-230 worldwide while OSE is entitled to receive a $48M upfront payment & additional $665M payment for clinical development, regulatory & commercial milestones plus global net-sales-based tiered royalties
- OSE-230 is a mAb that aims to activate ChemR23 to resolve chronic inflammation by modulating both macrophage & neutrophil functions
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie and Tentarix Biotherapeutics Join Forces for the Development of Biologics for Oncology and Immunology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
